Phase I Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients with Advanced Cancer

PURPOSE: To define the maximum tolerated dose (MTD), toxicities, and pharmacokinetics of 17-allylamino-17-demethoxygeldanamycin (17-AAG) when administered using continuous and intermittent dosing schedules. EXPERIMENTAL DESIGN: Patients with progressive solid tumor malignancies were treated with 17-...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
मुख्य लेखकों: Solit, David B., Ivy, S. Percy, Kopil, Catherine, Sikorski, Rachel, Morris, Michael J., Slovin, Susan F., Kelly, W. Kevin, DeLaCruz, Anthony, Curley, Tracy, Heller, Glenn, Larson, Steven, Schwartz, Lawrence, Egorin, Merrill J., Rosen, Neal, Scher, Howard I.
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: 2007
विषय:
Article
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC3203693/
https://ncbi.nlm.nih.gov/pubmed/17363532
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-06-1863
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन